Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.
Company Details
- Employees
- 70
- Address
- 1490 Obrien Dr, Menlo Park,california 94025,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- hexagonbio.com
- Keywords
- Officer jobs.
- HQ
- Menlo Park, California
Hexagon Bio Questions
Hexagon Bio's website is hexagonbio.com
Hexagon Bio's LinkedIn profile is https://www.linkedin.com/company/hexagon-bio
Hexagon Bio has
70 employees.
View email and phone details for 70
employees at Hexagon Bio.
Hexagon Bio's industry is
Biotechnology Research
Hexagon Bio's top competitors are
Revolution Medicines,
Arsenal Biosciences, Inc.,
Ideaya Biosciences,
Gilead Sciences,
Shiru,
Denali Therapeutics,
Genentech,
Maze Therapeutics,
Site Therapeutics,
Synthekine.
Hexagon Bio's categories are Biotechnology Research
